Superb Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 6.00 M
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
- Revenue Growth -9.66%
- Profit Growth -76.62%
- Ebitda -43.59%
- Net Worth 117.55%
- Total Assets 9.90%
About Superb Formulations
Superb Formulations Private Limited (SFPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 October 2015 (Nine years and four months 0 days old ). Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 6.00 M.
The company currently has active open charges totaling ₹2.00 Cr.
Sulakshan Parameswaran and Madanamuthu Parameswaran serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U15139TN2015PTC102475
-
Company No.
102475
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Oct 2015
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Superb Formulations?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sulakshan Parameswaran
|
Director | 06-Oct-2015 | Current |
|
Madanamuthu Parameswaran
|
Director | 06-Oct-2015 | Current |
Financial Performance of Superb Formulations.
Superb Formulations Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.66% decrease. The company also saw a substantial fall in profitability, with a 76.62% decrease in profit. The company's net worth Soared by an impressive increase of 117.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Superb Formulations?
In 2023, Superb Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.00 Cr
₹0
Charges Breakdown by Lending Institutions
- City Union Bank Limited : 1.92 Cr
- Others : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Jun 2017 | City Union Bank Limited | ₹1.92 Cr | Open |
| 28 Jul 2016 | Others | ₹0.75 M | Open |
How Many Employees Work at Superb Formulations?
Unlock and access historical data on people associated with Superb Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Superb Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Superb Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.